Comparative Pharmacology
Head-to-head clinical analysis: ACETOHEXAMIDE versus LOGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETOHEXAMIDE versus LOGEN.
ACETOHEXAMIDE vs LOGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin release from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels (K_ATP), causing membrane depolarization, calcium influx, and exocytosis of insulin-containing granules. Also may increase peripheral insulin sensitivity.
LOGEN (lofepramine) is a tricyclic antidepressant that primarily inhibits the reuptake of norepinephrine and, to a lesser extent, serotonin at the presynaptic nerve terminal, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminic, and alpha1-adrenergic blocking properties.
Initial: 250 mg orally once daily; maintenance: 250-1500 mg orally once daily or in divided doses twice daily.
1-2 tablets (5-10 mg loperamide) orally after first loose stool, then 1 tablet (5 mg) after each subsequent loose stool; maximum 8 tablets (40 mg) per day for acute diarrhea; 4-8 tablets (20-40 mg) daily in divided doses for chronic diarrhea.
None Documented
None Documented
Terminal elimination half-life: 6-12 hours (parent drug); ~5-6 hours (active metabolite hydroxyhexamide); clinical context: prolonged in renal impairment due to accumulation of active metabolite
Terminal half-life is 2-4 hours in adults with normal renal function; extends to 8-12 hours in renal impairment. Clinical context: requires frequent dosing or renal dose adjustment.
Renal: 85-90% (60-70% as unchanged drug, remainder as hydroxylated metabolite); biliary/fecal: <10%
Renal excretion dominates: 70-80% of the dose is eliminated unchanged in urine; biliary/fecal excretion accounts for 10-15%. Minimal hepatic metabolism.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic